Photo of Hernan Gonzalez/LinkedIn
Nov 27, 2023, 17:11
Hernan Gonzalez: This data provides new evidence of the benefit of molecular testing in well selected patients with indeterminate thyroid cytology
Quoting Hernan Gonzalez, on LinkedIn:
”We have just published a new prospective non-interventional study showing real-world clinic utility of ThyroidPrint. Up to 67% of patients undergoing molecular testing for indeterminate thyroid cytology were called benign (Benign Call Rate). With a minimum of 18 months of follow-up, 99% of these patients remained under surveillance. Furthermore, the post-test cancer probability in patients undergoing ThyroidPrint testing was 71% when compared to the 32% of patient that did not undergo testing. This data provides new evidence of the benefit of molecular testing in well selected patients with indeterminate thyroid cytology.”
For the article click here.
Source: Hernan Gonzalez/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 27, 2025, 08:58
Jun 27, 2025, 07:51
Jun 27, 2025, 07:37